Potential factors that affect electrocardiographic progression of interatrial block

Annals of Noninvasive Electrocardiology

Volumn 12, Issue 1, 2007, Pages 21-26

  Ariyarajah, Vignendra ^a   Kranis, Mark ^b   Apiyasawat, Sirin ^c   Spodick, David H ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c SAINT VINCENT HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Antihypertensive medication; Beta adrenergic blockers; Hypertension; Interatrial block; Progression

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; ELECTROCHEMISTRY; EVALUATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA;

AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIA; HEART BLOCK; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; RETROSPECTIVE STUDIES; TACHYCARDIA;

EID: 33846580652     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2007.00134.x     Document Type: Article

References (18)

1. Ariyarajah V, Asad N, Tandar A, et al. Interatrial block: Pandemic prevalence, significance, and diagnosis. Chest 2005;128(2):970-975.
2. Ariyarajah V, Apiyasawat S, Puri P, et al. Specific electrocardiographic markers of P-wave morphology in interatrial block. J Electrocardiol 2006;39:380-384.
3. Amar D, Shi W, Hogue CW Jr, et al. Clinical prediction rule for atrial fibrillation after coronary artery bypass grafting. J Am Coll Cardiol 2004;44(6):1248-1253.
4. Ariyarajah V, Mercado K, Apiyasawat S, et al. Correlation of left atrial size with P-wave duration in interatrial block. Chest 2005;128(4):2615-2618.
5. Goyal SB, Spodick DH. Electromechanical dysfunction of the left atrium associated with interatrial block. Am Heart J 2001;142:823-827.
6. Lorbar M, Levrault R, Phadke JG, et al. Interatrial block as a predictor of embolic stroke. Am J Cardiol 2005;95(5):667-668.
7. Ariyarajah V, Spodick DH. The Bachmann bundle and interatrial conduction. Cardiol Rev 2006;14:194-199.
8. Ariyarajah V, Spodick DH. Progression of partial to advanced interatrial block. J Electrocardiol 2006;39(2):177-179.
9. Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289(19):2560-2571.
10. World Health Organization. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17(2):151-183.
11. Ariyarajah V, Puri P, Kranis M, et al. Prevalence of interatrial block in the Program of All-inclusive Care for the Elderly (PACE). Am J Geriatr Cardiol 2006;15:174-177.
12. Bayes de Luna A, Cladellas M, Oter R, et al. Interatrial conduction block and retrograde activation of the left atrium and paroxysmal supraventricular tachyarrhythmia. Eur Heart J 1988;9(10):1112-1118.
13. Gonzalez MD, Contreras LJ, Cardona F, et al. Demonstration of a left atrial input to the atrioventricular node in humans. Circulation 2002;106(23):2930-2934.
14. Ariyarajah V, Apiyasawat S, Moorthi R, et al. Potential clinical correlates and risk factors for interatrial block. Cardiology 2006;105(4):213-218.
15. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101(22):2612-2617.
16. Zaman AG, Kearney MT, Schecter C, et al. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004;147:823-827.
17. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002;106(3):331-336.
18. Yusuf S, Sleight P, Pogue J. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-153.